Viamet discovers and develops "best-in-class" small molecule inhibitors of key metalloenzymes via an innovative and proprietary enzyme binding approach, our Metallophile^® Technology. The Metallophile Technology has allowed us to rapidly and cost-effectively discover and develop a portfolio of proprietary clinical compounds and drug candidates which address significant unmet medical needs and represent blockbuster commercial potential.

We have assembled a world-class team that comprises expertise in bioinorganic and medicinal chemistry, drug discovery and clinical development. Our senior managers have more than 125 years of combined pharmaceutical industry experience. The team is complemented by scientific and clinical advisors with broad expertise in bioinorganic chemistry, pharmaceutical development and clinical practice. Our scientific founders, Dr. Holden Thorp, Chancellor, The University of North Carolina, Chapel Hill, and Dr. Thomas O'Halloran, Morrison Professor of Chemistry and Cell Biology, Northwestern University, are recognized leaders in the field of bioinorganic chemistry.

The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc. and VPS-1, Inc. Viamet is based in the Research Triangle Park region of North Carolina, USA.